BOSTON--(BUSINESS WIRE)--Gentuity, LLC, an advanced imaging technology firm, today announced the first human use of the Vis-MTM High-Frequency Optical Coherence Tomography (HF-OCT) imaging system and probe. This represents a significant technological advance for the field of neurointervention, making high resolution intravascular imaging in the brain possible.
“This is an incredibly exciting milestone. The direct visualization technology we evaluated here offers unprecedented potential in the diagnosis and treatment of aneurysms, stroke, intra-cranial atherosclerotic disease (ICAD) and other neurological pathologies,” said Vitor Mendes Pereira, MD. “I am proud and honored to have the opportunity to perform the first cases. The system and imaging probes performed very well, integrating with our workflow seamlessly, and provided us with important information that we cannot obtain with any other technology - very impressive.”
The procedures were performed at St. Michael’s Hospital, a site of Unity Health Toronto, by neurosurgeon Prof. Vitor Mendes Pereira, Director of Endovascular Research and Innovation. They were performed in the neuro-angiography suite with a minimally invasive, endovascular approach.
“We are very pleased to have had the opportunity to work with the team at St. Michael’s Hospital and to contribute our novel high-resolution intracranial images to the care of these patients,” said David Kolstad, CEO of Gentuity. “These procedures reflect years of technical innovation, development, and extensive testing. They are an important step in our mission to develop a platform that will improve the understanding of target diseases, facilitate the development of novel therapies, and ensure optimal treatment delivery for the benefit of patients worldwide.”
Gentuity’s Vis-M neuro intravascular imaging probe has been designed to specifically address the challenges of navigating through the tortuous and delicate blood vessels of the brain. This imaging probe enables in-vivo micron level resolution at 250 frames per second providing high resolution images not only of the arterial wall and interventional therapies but also beyond the vessel wall.
This first-in-world experience will be presented in January at the ABC WIN Conference in Val d’Isere France.
“Because of Neuro HF-OCT, we will now be able, for the first time, to analyze and better understand different pathologies and the results of our neurointerventional therapies. It is a real game changer in the cerebrovascular field,” said Prof. Pedro Lylyk MD, Neurosurgeon, Director and CEO of ENERI (Equipo de Neurocirugía Endovascular y Radiología Intervencionista) in Buenos Aires, Argentina.
“Today, we welcome the new era of intravascular imaging in intracranial circulation with this new technology,” said Matt Gounis PhD, Professor at the UMass Medical School Department of Radiology and Director of New England Center for Stroke Research. “Revolutions in neurointerventional imaging, from the discovery of x-rays over 120 years ago, to 3-dimensional imaging in the angiography suite 20 years ago, occur roughly once in a generation. The work demonstrated by Dr Pereira and his team in these first human cases is profound – direct imaging of the pathology and its relationship to devices transforms treatment decisions, and the fundamental understanding of cerebrovascular pathology.”
“Gentuity is committed to accelerating the improvement of neurovascular patient care. With our proprietary neuro intravascular imaging system and AI data platform, we are able to work closely with our clinical and preclinical partners to collaborate and enhance our understandings and patient care together,” said David Kolstad, CEO of Gentuity, LLC. “We have been very fortunate to work with leaders in the field of neurointervention including Dr Vitor Mendes Pereira, Dr Ajit Puri, Dr Matt Gounis, Dr Pedro Lylyk, Dr Demetrius Lopes, Dr Ricardo Hanel, Dr Conrad Liang, Dr Vaia Anagnostakou and others to reach this important milestone.”
About Gentuity
Gentuity, an advanced imaging and AI firm based in Massachusetts, is dedicated to developing next-generation intravascular devices that enable fundamental transformation of cardiovascular and neurovascular patient care. The Gentuity system is a proprietary platform, incorporating AI, that aims to enhance procedural success and clinical decision making. Gentuity strives to bring the benefits of high-resolution intravascular imaging to more patients and hospitals around the world.
